secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0000875320-24-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q4/FY23 revenue $2.52B/$9.87B; FY24 guidance $10.55-$10.75B; vanza triple and VX-548 NDAs by mid-2024
--------------------------------------------------------------------------------

- FY23 product revenue $9.87B (+11% YoY); Q4 revenue $2.52B (+9% YoY).
- FY24 product revenue guidance $10.55-$10.75B, reflecting CF growth and CASGEVY launch.
- Completed pivotal studies for vanzacaftor triple (CF) and VX-548 (acute pain); NDAs to FDA by mid-2024.
- CASGEVY approved in U.S., Great Britain, KSA, Bahrain; CHMP positive opinion; activated ATCs.
- VX-880 Phase 1/2 study on protocol-specified pause; VX-264 advanced to Part B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000012/0000875320-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000012/vrtx-20240205.htm
  HTML page:      https://secwatch.observer/filing/0000875320-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer